Format

Send to

Choose Destination
IDrugs. 2006 Aug;9(8):554-9.

Making high-affinity T-cell receptors: a new class of targeted therapeutics.

Author information

1
Avidex Ltd, 57C Milton Park, Abingdon, Oxon, OX14 4RX, UK. rebecca.ashfield@avidex.com

Abstract

The last two decades have seen the development of an expanding array of monoclonal antibodies, which are proving to be effective treatments for both cancer and autoimmune disease. A related protein, the human T-cell receptor (TCR), is able to access a new range of targets for which antibodies are unsuitable, and is being developed as a new class of protein therapeutics. Similar to antibodies, TCRs have a specific target and therefore a limited potential for side effects; however, a possible drawback with these receptors is that their natural affinity is low. This problem has recently been overcome using phage display to increase TCR affinity up to a million-fold.

PMID:
16871464
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center